Related Experiment Video
Updated: Oct 15, 2025
Experimental Model of Ligature-Induced Peri-Implantitis in Mice
Published on: May 17, 2024
A Novel Modified-Curcumin Promotes Resolvin-Like Activity and Reduces Bone Loss in Diabetes-Induced Experimental
Jie Deng1, Lorne M Golub2, Hsi-Ming Lee2
1Department of Orthodontics, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing, 100081, People's Republic of China.
A novel curcumin derivative, CMC2.24, effectively combats inflammation and bone loss in diabetic periodontitis. This therapeutic strategy reduces inflammatory markers and promotes healing, offering hope for managing complex chronic conditions.
Area of Science:
- Biomedical Science
- Oral Biology
- Pharmacology
Background:
- Diabetic periodontitis presents a clinical challenge due to bidirectional inflammatory and collagenolytic exacerbation.
- Current treatments focus on bacterial load reduction, neglecting crucial hyper-inflammation and excessive collagenolysis control.
- Novel therapeutic strategies are needed to modulate host response and promote inflammation resolution in periodontitis.
Purpose of the Study:
- To evaluate the therapeutic impact of a chemically modified curcumin, CMC2.24, on the host inflammatory response in a diabetic rat model.
- To assess CMC2.24's ability to modulate key inflammatory mediators and bone loss associated with diabetes-induced periodontitis.
Main Methods:
- Type 1 diabetes induced via streptozotocin; periodontal breakdown monitored.
- CMC2.24 or vehicle administered orally to diabetic rats for 3 weeks.
- Analysis included Micro-CT for bone morphometrics, gelatin zymography for MMPs, ELISA for cytokines/resolvins, and cell migration assays.
Main Results:
- CMC2.24 normalized macrophage accumulation and chemotaxis, significantly reduced MMP-9 and pro-inflammatory cytokines.
- Treatment markedly increased resolvin D1 (RvD1) levels in peritoneal exudates and washes.
- CMC2.24 significantly inhibited alveolar bone loss, preserving height, volume, and mineral density.
Conclusions:
- CMC2.24, a modified curcumin, effectively resolves local and systemic inflammation in hyperglycemic diabetic rats.
- The compound suppresses collagenolytic matrix metalloproteinases (MMPs) and pro-inflammatory cytokines, mitigating bone loss.
- CMC2.24 represents a promising novel therapeutic strategy for periodontitis complicated by chronic diseases like diabetes.
